S 4472: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

S 4472 in plain English: This bill reauthorizes through FY2031 federal programs that fund research and development of treatments for ALS (Lou Gehrig's disease) and other neurodegenerative diseases. It continues grants through the NIH and FDA, updates reporting and safety requirements for those grants, and maintains a public-private partnership to support treatment development and regulatory review.

Stated purpose

To reauthorize through fiscal year 2031 federal programs that fund research and development of drugs and therapies for ALS (Lou Gehrig's disease) and other neurodegenerative diseases, and to add new oversight and reporting requirements to those programs.

Key points

• Reauthorizes NIH grants for ALS drug research and FDA grants for ALS and neurodegenerative disease therapy development through FY2031
• Requires NIH to assess safety and efficacy data when considering grant renewals and to set timelines for clinical trial enrollment
• Requires FDA to publish a five-year action plan every five years for developing and providing access to ALS and rare neurodegenerative disease drugs
• Continues a Public-Private Partnership between FDA and NIH supporting treatment development and regulatory review for neurodegenerative diseases
• Requires GAO and HHS to report on the impacts of these grant programs

Arguments supporters make

• ALS is a fatal disease with few treatment options, and keeping these programs funded gives patients their best chance of accessing experimental therapies that might help them.
• The new safety reporting and enrollment requirements make the program more rigorous, ensuring taxpayer dollars go to research that is actually producing useful data.
• Requiring the FDA to publish and update five-year plans creates a clear roadmap and public accountability for progress on rare neurodegenerative diseases.

Arguments opponents make

• Reauthorizing existing programs without a thorough evaluation of what they have achieved may continue spending on approaches that have not yet produced proven treatments.
• Adding new reporting mandates and conditions on grantees could slow down research or discourage participation by smaller institutions with limited administrative capacity.
• Focusing federal resources heavily on ALS, while a serious disease, may draw funding and attention away from other neurodegenerative conditions affecting larger numbers of patients.

Tradeoffs

Extending and expanding these programs increases federal spending and regulatory requirements in hopes of faster treatment development, but those added costs and obligations must be weighed against uncertain timelines for producing safe, effective therapies for patients.

Current status in Congress: Passed Senate.

NewsClear — neutral news & congressional tracking · Bill of the Week